FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease

Home
news
FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease

FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease

Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS

Amylyx announces data in Muscle & Nerve demonstrating survival benefit

Recent Posts

Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board